We have developed a novel class of specifically engineered, dimerized cyclodextrin (CD) nanostructures for the encapsulation of toxic biomolecules such as 7-ketocholesterol (7KC). 7KC accumulates over time and causes dysfunction in many cell types, linking it to several age-related diseases

Abstract Modified cyclodextrins (CDs) consist of a distribution of different structures with different number and location of the substituted groups. Among the most important applications of these molecules is their use as an enabling excipient in pharmaceutical formulations to provide

The formation of small hybrid aggregates between excipient and drug molecules is one of the mechanisms that contributes to the solubilization of active principles in pharmaceutical formulations. The characterization of the formation, governing interactions and structure of such entities is

Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed a partnership and technology acquisition agreement with MD.USE Innovative Solutions, SL. Read more

MD.USE, together with more than 200 representatives of companies and research centers in the biotechnology, agro-food and biomass sectors will be present at the Agrobiotech Innovation Meeting on 26 and 27 October, a biennial event that reaches the second edition

MD.USE talks in the program radio “La bolsa y la vida” https://www.ivoox.com/capital-bolsa-vida-mentoring-audios-mp3_rf_18552660_1.html?autoplay=true

  Today was the awards ceremony of the IV Bioga Awards that had nine candidates. MD.USE was candidate in the Best Biotech Business Idea modality, in this modality are valued innovative projects or newly created companies that value revolutionary products